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Abstract
Background: Del Nido (DN) cardioplegia, a calcium-free, hyperkalemic solution containing lidocaine and
magnesium has been developed to help reduce intracellular calcium influx and the resulting myocyte damage in
the immediate postischemic period following cardiac arrest. DN cardioplegia has been used for pediatric cardiac
surgery but its use in complex reoperative surgery has not been studied. We specifically report the outcomes of
patients undergoing reoperative cardiac surgery after previous coronary artery bypass grafting with a patent
internal mammary artery (IMA).
Methods: Patients undergoing reoperative cardiac surgery with prior coronary bypass grafting surgery were studied
between 2010 and 2013. Fourteen patients were identified who required continued retrograde cardioplegia
administration. In all cases, an initial antegrade dose was given, followed by continuous retrograde administration.
Demographics, co-morbidities, intra-operative variables including cardioplegia volumes, post-operative complications,
and patient outcomes were collected.
Results: The mean age of all patients was 73.3+/−6.7 years, and 93 % were male. Aortic cross clamp time and
cardiopulmonary bypass times were 81+/−35 and 151+/−79 mins, respectively. Antegrade, retrograde and total
cardioplegia doses were 1101+/−398, 3096+/−3185 and 4367+/−3751 ml, respectively. An average of 0.93+/−0.92
inotropes and 1.50+/−0.76 pressors were used on ICU admission after surgery. ICU and total hospital lengths of stay
were 5.5+/−7.4 and 9.6+/−8.0 days, respectively. Complications occurred in two patients (14 %) (pneumonia and
prolonged mechanical ventilation) and new arrhythmias occurred in five patients (36 %) (four new-onset atrial
fibrillation and one pulseless electrical activity requiring 2 min of chest compression). No perioperative myocardial
infarctions were noted based on electrocardiograms and cardiac serum markers. Postoperatively, left ventricular
function was preserved in all patients whereas two patients (14 %) had mild decrease in right ventricular function as
assessed by echocardiography. No mortality was observed.
Conclusion: Del Nido cardioplegia solution provides acceptable myocardial protection for cardiac surgery that requires
continuous retrograde cardioplegia administration. DN cardioplegia’s administration in a continuous retrograde fashion
with a patent IMA is believed to provide adequate myocardial protection while avoiding injuring the IMA through
dissection and clamping.
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Background
Retrograde cardioplegia via the coronary sinus has be-
come an essential method to deliver cardioplegia to the
left ventricle, particularly in the setting of critical coron-
ary stenosis, aortic insufficiency, or other factors pre-
cluding antegrade cardioplegia administration [1].
Patent bypass grafts after coronary artery bypass graft-
ing (CABG), such as an internal mammary artery
(IMA) graft, can prevent full cardioplegic arrest if un-
able to be isolated and clamped; in this situation, con-
tinuous retrograde cardioplegia has been administered
using whole blood cardioplegia with reduced potas-
sium concentration to achieve ventricular fibrillatory
arrest. The most popular technique to deal with a pa-
tent IMA is to clamp both the aorta and the patent
graft and administer antegrade and retrograde cardio-
plegia [2]. However, if an area of the myocardium is
very dependent on the patent IMA, clamping the graft
may cause inadequate myocardial protection. More-
over, the dissection and clamping of the IMA have
been linked with the associated morbidity and mortal-
ity of the procedure as they could cause inadvertent in-
jury to the graft [3]. Other groups have reported
satisfactory results with selective use of continuous
retrograde cardioplegia administration in patients
whose IMA was deemed technically challenging to
safely dissect and clamp [2, 4].
Del Nido cardioplegia (DN) (Compass- Baxter
Healthcare Inc., Edison, NJ) has been in use for over
20 years in the pediatric populations. It is delivered
cold (4 °C) at a ratio of one part blood to four parts
crystalloid, and achieves arrest using a low calcium,
hyperkalemic solution with lidocaine and magnesium
additive for a total volume of 1 L [5–8]. After mixture
of the blood and crystalloid components, the final con-
centrations of Na+, K+ and Ca2+ in the DN solution are
respectively: 38, 22 and 0.24 mmol/L. The safety of its
use in adult cardiac surgery has been recently reported
in three series from our institution evaluating specific
situations of cardiac surgeries [9–11]. These studies
showed that DN cardioplegia could be safely used in
patients undergoing CABG for acute myocardial infarc-
tion (AMI), aortic valve replacement (AVR) or isolated
reoperative AVR. They all showed that morbidity and
mortality in patients receiving DN cardioplegia is
comparable to those of patients receiving standard
whole blodd (WB) cardioplegia. We report our use of
DN cardioplegia given as a continuous retrograde in-
fusion in the setting of complex, reoperative cardiac
surgeries with a patent prior IMA unable to be iso-
lated. DN solution given in a continuous retrograde
fashion is, unlike the original solution, made of four
units of blood to one unit of crystalloid in order to
reduce hemodilution.
Methods
All patients who underwent reoperative cardiac surgeries
after prior CABG between 2010 and 2013 were reviewed
retrospectively, and a total of 14 patients were identified
who received continuous retrograde DN. In all cases, a
patent IMA was present and was not clamped during
cross-clamp. Patient characteristics were collected, in-
cluding age, gender, body surface area, pre-operative co-
morbidities and surgical risk factors [hyperlipidemia,
prior myocardial infarct (MI), hypertension, stroke,
chronic obstructive pulmonary disease, chronic kidney
disease with baseline creatinine >2.0 mg/dL, atrial fibril-
lation, congestive heart failure by New York Heart Asso-
ciation functional classification, prior CABG], left
ventricular ejection fraction (LVEF), number of ino-
tropes and vasopressors on intensive care unit (ICU) ad-
mission, days on ventilator, length of postoperative ICU
stay (ICULOS), total post-operative hospital length of
stay (THLOS), in-hospital mortality, and post-operative
complications [transfusion, sepsis or endocarditis, ster-
nal wound infection, gastrointestinal bleeding, MI, reop-
eration for bleeding, acute renal injury, stroke, transient
ischemic attach, need for permanent pacemaker, pro-
longed mechanical ventilation and need for reintuba-
tion]. This study met all guidelines of the Institutional
Review Board of Columbia University Medical Center.
Using mild systemic hypothermia (32–34 ° C), ante-
grade cardioplegia was first administered after cross
clamp (XC) (500–1000 cc), followed by 500–750 cc
retrograde. DN cardioplegia was the only cardioplegia
solution used and was delivered at a temperature of 4 °
C. For the initial antegrade and retrograde doses, the so-
lution was administered as a 1:4 blood to crystalloid ra-
tio with concentrations of Na+, K+, Ca2+, Mg2+ and
lidocaine of respectively: 38, 22, 0.24, 6.6 and 104 mg/L.
Once ventricular fibrillation was achieved (typically at
approximately 1 L), cardioplegia was switched to con-
tinuous retrograde using a 4:1 blood to crystalloid ratio
to prevent hemodilution, the modified solution has con-
centrations of Na+, K+, Ca2+, Mg2+ and lidocaine of re-
spectively: 115, 9.2, 1, 2.4 and 26 mg/L (Tables 1 and 2).






Carrier (1 L) D5W Plasma-lyte A
Blood: Crystalloid ratio 4:1 1:4
KCl (mEq) 80 26
NaHCO3 (mEq) 30 13
Mannitol (g) 12.5 3.3
Lidocaine (mg) 0 130
Magnesium (g) 0 2
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Retrograde flow was maintained at approximately 40 ml/
kg/min for a coronary sinus pressure of 20–30 mmHg.
Particular attention was made to continuously check the
coronary sinus balloon pressure and maintain it at 20–
30 mmHg and to frequently watch the left main coronary
ostia to check for blood return. No redosing was required.
However, if significant electrical activity was encountered,
a full 1:4 dose cardioplegia dose would have been given
retrograde or via the coronary ostia.
Cardioplegia was intermittently interrupted for less
than 5 min for the purposes of visualization, especially
during valve debridement and when placing annular su-
tures in the left coronary sinus. The operative details
that were collected included cardiopulmonary bypass
(CPB) and XC time, ischemic time, doses of antegrade
and retrograde cardioplegia, lowest body temperature
and number of transfusions.
Results
Patient demographics
The baseline pre-operative patients’ characteristics are
summarized in Table 3. Mean age was 73.3 ± 6.7 years
(range 61–83 years). Thirteen patients (93 %) were
males, and most of them (86 %) had hypertension and
dyslipidemia. Mean LVEF was 44 ± 16 %. The types of
reoperative surgeries were as follows: nine isolated Aor-
tic Valve Replacement (AVR), 1 isolated Mitral Valve Re-
placement (MVR), 1 AVR/MVR/Tricuspid Valve Repair
(TVr), 1 CABG/AVR/Mitral Valve repair (MVr), 1
MVR/TVr, and 1 Aortic dissection repair. Mean Society
of Thoracic Surgeon predicted risk of mortality score
was 4.3 ± 2.1.
Intra-operative variables
Total CPB and XC times were within an acceptable
range, 151 ± 79 and 81 ± 35 min respectively, and no in-
traoperative complications related to cardioplegia ad-
ministration were noted. Antegrade, retrograde and total
cardioplegia doses were 1101 ± 398, 3096 ± 3185 and
4367 ± 3751 ml, respectively. Ventricular fibrillation was
achieved in all patients. Mechanical circulatory support
was not required in any patient whereas an intra-aortic
balloon pump was placed in only one patient. The intra-
operative measurements are summarized in Table 4.
Postoperative outcomes
Postoperative complications occurred in two patients
(14 %), both had pneumonia complicated by sepsis and a
prolonged mechanical ventilation time (8 and 24 days).
Five patients (36 %) had new arrhythmias postopera-
tively (four had new-onset atrial fibrillation and one had
pulseless electrical activity requiring 2 min of chest com-
pression). ICULOS and THLOS were respectively 5.5 ±
7.4 and 9.6 ± 8.0 days. On average, patients needed 0.93
± 0.92 inotropes and 1.50 ± 0.76 vasopressors on ICU ad-
mission. No perioperative MIs (PMI) [12] were diag-
nosed. Biomarkers were ordered whenever symptoms
and/or EKG signs of possible PMI were suspected, as
well as when patients were enrolled in clinical trials
mandating serial cardiac markers level assessment.
Table 2 Final concentrations in del Nido Cardioplegia solutions
(after mixing with blood)




Carrier Plasma-lyte A Plasma-lyte A
Blood: Crystalloid ratio 1:4 4:1
K+ (mmol/L) 22 9.2
Na+ (mmol/L) 38 115
Ca2+ (mmol/L) 0.24 1.0
Lidocaine (mg/L) 104 26
Mg2+ (mmol/L) 6.6 2.4
Table 3 Baseline Demographics
Number 14
Age, year (mean ± SD) 73.3 ± 6.7
Male, n (%) 13 (93)
BMI, kg/m2 (mean ± SD) 27 ± 4.0
BSA m2 (mean ± SD) 1.97 ± 0.16
Diabetes, n (%) 5 (36)
Hypertension, n (%) 12 (86)
Dyslipidemia (%) 12 (86)
COPD, n (%) 2 (14)
PVD, n (%) 4 (29)
Stroke, n (%) 2 (14)
Atrial fibrillation, n (%) 5 (36)
Creatinine, > 2 (mg/dL) n (%) 2 (14)
LVEF, % (mean ± SD) 44 ± 16
NYHA grade (mean ± SD) 2.1 ± 1.1
STS score (mean ± SD) 4.3 ± 2.1
Definitions: BMI body mass index, BSA body surface area, COPD chronic
obstructive pulmonary disease, PVD peripheral vascular disease, LVEF left
ventricular ejection fraction, NYHA New York Heart Association, STS society of
thoracic surgery
Table 4 Intraoperative measurements
Cross-clamp time (min, mean ± SD) 81 ± 35
CPB time (min, mean ± SD) 151 ± 79
ACP dose (mL, mean ± SD) 1101 ± 398
RCP dose (mL, mean ± SD) 3096 ± 3185
TCP dose (mL, mean ± SD) 4367 ± 3751
Lowest temperature (°C, mean ± SD) 32.36 ± 3.67
Definitions: CPB cardiopulmonary bypass, ACP antegrade cardioplegia, RCP
retrograde cardioplegia, TCP total cardioplegia
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Troponin I and CKMB were ordered for four patients
(29 %), of which actually only one had a suspicion of
PMI, the other three were part of clinical trials. Average
postoperative Troponin I was 1.01 ± 0.335 ng/mL (refer-
ence range 0.00–0.008 ng/mL) and CKMB 3.58 ±
3.47 ng/mL (reference range 0.5–5.5 ng/mL). Immediate
preoperative and postoperative trans-esophageal echo-
cardiographs (TEE) as well as predischarge transthoracic
echocardiographs were reviewed in all patients to assess
ventricular function preservation. All patients had pres-
ervation of left ventricular (LV) function and only three
patients (21 %) had slightly worsened right ventricular
(RV) function immediately postop (no dysfunction preop
to mild dysfunction postop), which in 1 case (7 %) recov-
ered completely by the time the patient was discharged.
Moreover, two patients (14 %) had an improvement in RV
function from preop to postop with a mild dysfunction
not appreciated on the postop TEE. All patients were dis-
charged from the hospital alive for a 0 % 30-day and in-
hospital mortality. Follow-up duration was 361 ± 356 days
and midterm results were excellent with a 100 % survival
rate. Moreover, on follow-up echocardiography, there was
preservation of LV function in all 14 patients and no new
RV dysfunction. Postoperative variables are summarized
in Table 5.
Discussion
The patent IMA graft poses a special concern for sur-
geons - its dissection and isolation can pose risk, and in-
jury to this vessel during surgery is associated with
extremely high rates of mortality [13]. Thus, continuous
retrograde administration of cardioplegia in the midst of
a patent IMA has become an accepted technique for ef-
fective myocardial preservation [14]. Other strategies to
manage myocardial protection during reoperative cardiac
surgeries with a patient IMA have been described. The
most popular technique is clamping both the aorta and
the patent IMA graft with antegrade and retrograde infu-
sion of cardioplegia. The main limitation of that technique
are the fact that some areas of the myocardium might be
dependent on the patent graft and simply clamping it may
lead to suboptimal myocardial protection, as well as the
risk of injury to the graft that comes with dissection and
clamping [2, 3]. Other strategies that have been described
but have not gained widespread popularity are: deep
hypothermia alone [15], continuously perfused beating
heart [16], endovascular occlusion or supraclavicular
clamping of the patent IMA [17, 18]. Despite providing
adequate control of blood flow through the graft, manipu-
lation of the graft by itself can cause injury and should
probably be avoided whenever possible. Here we report
our experience with the combination of antegrade, retro-
grade and continuous retrograde hypothermic cardiople-
gia through a patent IMA using Del Nido cardioplegia, a
single dose hyperkalemic agent. Our data suggests that we
achieved effective myocardial preservation using continu-
ous retrograde administration, as evidenced by the ab-
sence of perioperative myocardial infarction, a good LV
and RV function preservation, reasonable CPB and XC
times, low amount of vasoactive medications post-bypass,
and the lack of need for additional mechanical circulatory
assistance. Thus, the strategy of antegrade, retrograde, and
continuous retrograde cardioplegia administration pro-
vided sufficient protection for surgery to be completed
without significant hindrance. Spontaneous recovery of
rhythm occurred in all patients, and there was only one
case of low cardiac output syndrome which required the
intraoperative insertion of an IABP. Part of these positive
outcomes may be attributed to the fact that the anterior
wall of the LV is continuously perfused via the IMA.
Nonetheless, use of DN cardioplegia does offer some dis-
tinct advantages, such as uninterrupted conduct of sur-
gery, stabilization of calcium handling regulation during
the ischemic period [19], less need for systemic cooling
and a lower total volume of cardioplegia.
Although not fully understood yet, ischemia-reperfusion
injury is thought to be at least partly due to an increase in
intracellular calcium concentrations in postischemic myo-
cytes. This increase in Ca2+ is related to an increase in
intracellular Na+ during the ischemic period, causing the
Na+/ Ca2+ channel to increase calcium influx [20-22] . As
a result of high levels of intracellular Ca2+, the myocytes
hypercontract causing irreversible damage to the cytoskel-
eton and even cell death [20] . Therefore, Del Nido cardio-
plegia provides a theoretical advantage over other
cardioplegia solutions in that it is calcium-free and con-
tains lidocaine, an Na+ channel blocker, as well as magne-
sium, a calcium competitor. All of these components
contribute to limiting calcium influx in the postperfusion
phase. The effectiveness of these mechanisms has been
Table 5 Postoperative variables
Inotropes on ICU admission, number (mean ± SD) 0.93 ± 0.92
Pressors on ICU admission, number (mean ± SD) 1.50 ± 0.76
Ventilation, days (mean ± SD) 3.6 ± 6.5
PRBCs, units (mean ± SD) 2.86 ± 4.96
Post-op EF, % (mean ± SD) 45 ± 14
ICULOS, days (mean ± SD) 5.5 ± 7.4
THLOS, days (mean ± SD) 9.6 ± 8.0
Complications, n (%) 2 (14)
New arrhythmia, n (%) 5 (36)
30-days Mortality, n (%) 0 (0)
Follow-up duration, days (mean ± SD) 361 ± 356
Cumulative mortality, n (%) 0 (0)
Definitions: PRBCs packed red blood cells, EF ejection fraction, ICULOS intensive
care unit length of stay, THLOS total hospital length of stay
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demonstrated in both animal and pediatric hearts, while
DN-arrested rats hearts had a significantly lower intracel-
lular calcium levels when compared to hearts arrested
with regular whole blood (WB) cardioplegia [23], pediatric
patients receiving DN solution had in turn a reduction in
troponin T release following surgery compared to patients
receiving the WB solution [19].
A lower total volume of cardioplegia allows a reduction
of hemodilution while on bypass and consequently a de-
creased need for transfusion. The advantages of decreasing
hemodilution have been demonstrated with WB or un-
diluted blood (microplegia) cardioplegia solutions, which
offer a better myocardial protection [24] and limit myocar-
dial edema [25] compared with crystalloid cardioplegia.
Conclusion
As a conclusion, del Nido cardioplegia solution can be
used as a safe alternative to whole blood solutions in
cardiac surgeries requiring the administration of con-
tinuous retrograde cardioplegia.
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